Filing Flows › Niagen Bioscience (NAGE) › Gross margin
Niagen Bioscience (NAGE) gross margin by quarter
Niagen Bioscience's gross margin was 64.8% in Q2 2026 (second quarter 2026), +1.4 pts from Q1 2026. Over the last 6 quarters it ranged from 63.4% (Q1 2025) to 65.0% (Q2 2025).
| Quarter | Gross margin | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | 64.8% | +1.4 pts | -0.2 pts |
| Q1 2026 | 63.5% | -0.7 pts | +0.0 pts |
| Q4 2025 | 64.1% | -0.4 pts | — |
| Q3 2025 | 64.5% | -0.5 pts | — |
| Q2 2025 | 65.0% | +1.6 pts | — |
| Q1 2025 | 63.4% | — | — |
Q2 2026 at a glance
Niagen Bioscience, Q2 2026: revenue $29.8M (-4% year over year), operating margin 2.4%, net earnings $963K, operating cash flow $2.8M. The chart follows the revenue to costs, profit and cash.
Questions
What is Niagen Bioscience's gross margin?
Niagen Bioscience's gross margin was 64.8% in Q2 2026 (second quarter 2026), +1.4 pts from Q1 2026.
How has Niagen Bioscience's gross margin changed?
Over the last 6 quarters it ranged from 63.4% (Q1 2025) to 65.0% (Q2 2025).